Resistance following failure of injectable cabotegravir/rilpivirine may limit future treatment options
Intermittent HIV treatment dosing may be a response to the funding crisis, but adolescent study raises concerns
Integrase inhibitor resistance after treatment failure more common in treatment-experienced people
Dolutegravir resistance very rare after a switch - even with detectable HIV
Lamivudine resistance mutation may persist for many years in some people with HIV
Injectable HIV treatment underway in England and largely effective, but a couple of breakthrough cases raise concern
Caution advised when prescribing long-acting injectable cabotegravir and rilpivirine to avoid drug resistance
Dissent on doxyPEP: recent guidelines becoming more cautious
Top 5 HIV treatment stories from CROI 2024
